This is the type of article that should get a sticky note or be put on the DD portion of the board for possible new investors to read.  Seems a lot more people than just CTIX development team/ mgt team believe Kevetrin is the real deal.

Also, since we are dealing with people with terminal tumors (as I understand the candidates to be) why start low dosage and work up?  Why not start high dose and work down?  You may lose a few patients (I am sure many, many volunteers would still sign up for a possible cure) but the time you save would save many, many more lives over 15 months or so if you could hone in on the optimum dosage right away.  I am not worried about the time for Kevetrin to be proven, I am worried for the people that will die over the next 15 months that would have had a chance if Kevetrin could have been made available in strong dosage.  My Dad died of a brain tumor and we knew going in he probably had a very low probability coming out of surgery with his brain intact if he did live.  Thus, he would have volunteered in a heartbeat to try and help find a cure by allowing a massive dose with the complete understanding it could kill him.  He really had nothing to lose.

IMO there should be a vastly different trial approach to products for terminal conditions versus non-life threatening conditions and in fact they should be almost completely opposite.  Just an observation from one with no medical background.  Kind of like war, you have to sacrifice a few at times to save the large population.